Class summary at a glance.

Every drug in the Vitamin D2 Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $5.4Mcombined across class
Total Rx claims: 44K12K unique beneficiaries
Generic mfrs (active): 19across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Paricalcitol

Brand: Zemplar · 42K Part D claims (CY24) · 12K beneficiaries · First FDA approval: 1998-04-17

10 generic mfrs 252 plans require PA Discontinued

Low NADAC$1.06

→

Avg plan cost$1.46

Part D spend $4.5M 1× spread, current vs floor

Class share

83%

of class CY24 spend

View profile →

Doxercalciferol

2K Part D claims (CY24) · 580 beneficiaries · First FDA approval: 2019-09-26

9 generic mfrs 93 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $902583

Class share

17%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.